0HX7.LSE Adicet Bio, Inc.
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -69.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 0HX7.LSE undervalued?
Graham numberThe Graham number of Adicet Bio, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Adicet Bio, Inc. fundamental analysis
No fundamental analysis for Adicet Bio, Inc. yet.
Adicet Bio, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Adicet Bio, Inc.
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-spec…
Full company profileAdicet Bio, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Adicet Bio, Inc. annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | - | 8.18M | 995K | 17.9M | 9.73M | 25.0M | - | - | - | - |
| Gross Profit | - | -5.00K | 8.10M | 870K | 17.9M | 9.73M | 20.0M | -6.10M | -6.47M | -6.38M | -5.08M |
| Operating Income | -1.00K | -18.9M | -39.7M | -31.4M | -32.1M | -61.4M | -72.6M | -152M | -128M | -122M | -87.7M |
| EBITDA | -1.00K | -18.9M | -37.5M | -30.2M | -37.4M | -57.9M | -64.7M | -137M | -111M | -116M | -82.7M |
| Net Income | -1.00K | -33.8M | -37.6M | -28.1M | -36.7M | -62.0M | -69.8M | -143M | -117M | -117M | -83.2M |
| EPS | 0.00 | -944 | -442 | -210 | -80 | -32 | -27 | -53 | -21 | -17 | -7.74 |
| Balance Sheet | |||||||||||
| Total Assets | - | 55.2M | 110M | 81.6M | 154M | 339M | 331M | 207M | 220M | 192M | 148M |
| Total Liabilities | - | 5.50M | 5.74M | 142M | 44.0M | 35.8M | 38.4M | 37.1M | 33.6M | 33.1M | 28.0M |
| Shareholders' Equity | - | 49.7M | 104M | -60.4M | 110M | 303M | 292M | 170M | 187M | 159M | 120M |
| Cash & Short-term Investments | - | 53.3M | 108M | 62.4M | 94.6M | 278M | 258M | 160M | 176M | 159M | 118M |
| Total Debt | - | - | 3.11M | 114M | 21.6M | 20.9M | 21.0M | 20.9M | 17.2M | 14.7M | 12.9M |
| Cash Flow | |||||||||||
| Operating Cash Flow | - | -11.6M | -36.4M | -27.9M | -41.7M | -51.3M | -45.1M | -93.7K | -92.4M | -95.2M | -82.6M |
| Capital Expenditure | - | 44.0K | 362K | 1.07M | 990K | 13.0M | 16.8M | 4.46K | 1.12M | 1.74M | 478K |
| Free Cash Flow | - | -11.6M | -36.8M | -29.0M | -42.7M | -64.4M | -61.9M | -98.2K | -93.5M | -97.0M | -83.1M |
| Ratios | |||||||||||
| ROE | - | -68.0% | -36.1% | - | -33.4% | -20.5% | -23.9% | -83.8% | -62.8% | -73.4% | -69.3% |
| ROA | - | -61.2% | -34.2% | -34.5% | -23.8% | -18.3% | -21.1% | -68.8% | -53.2% | -60.7% | -56.2% |
| Net Profit Margin | - | - | -459.8% | -2,827.9% | -204.9% | -637.2% | -279.3% | - | - | - | - |
| Debt to Equity | - | - | 0.03x | - | 0.20x | 0.07x | 0.07x | 0.12x | 0.09x | 0.09x | 0.11x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Adicet Bio, Inc. dividends
Adicet Bio, Inc. has not paid dividends in the last 9 fiscal years.
Last stock split: 0.0625:1 on Dec 30, 2025.
Who owns Adicet Bio, Inc.
- Insiders 6.44%
- Institutions 65.75%
- Public & others 27.81%
- Free float 7.18M
Adicet Bio, Inc. company profile
- Company name
- Adicet Bio, Inc.
- Ticker
- 0HX7.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 102
- Fiscal year end
- December
- Address
- 131 Dartmouth Street, Boston, MA, United States, 02116
- Phone
- 650 503 9095
- Website
- adicetbio.com
About Adicet Bio, Inc.
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in Boston, Massachusetts.
Adicet Bio, Inc. management
6- Mr. Chen Schor BA, CPA, M.B.A.CEO, President & Director · born 1972
- Dr. Blake Aftab Ph.D.Senior VP & Chief Scientific Officer · born 1981
- Dr. Lloyd Klickstein M.D., Ph.D.Interim Chief Medical Officer & Director · born 1957
- Mr. Brian Nicholas Harvey M.B.A.Chief Financial Officer · born 1961
- Dr. Donald Healey Ph.D.Chief Technology Officer · born 1962
- Ms. Amy LockeChief Human Resource Officer